The Death Of Buy And Hold Has Been Greatly Exaggerated
Market indices are strong, but underlying breadth and momentum are weakening, notes David Keller, suggesting limited upside and a better buying opportunity later in the year. Tech remains the leading sector, though valuations are stretched.
Non-Tech Markets Lose Steam; Nasdaq Approaches Record High
The Dow slipped 106 points, -0.25%, while the Nasdaq gained +61 points, +0.31% -- approaching new highs.
Buy 5 High-Flying Non-Tech Nasdaq-Listed Stocks of H1 to Gain in H2
Nasdaq is flat in first-half 2025, but SFM, RGLD, TRI, WWD and EXEL are soaring, each up over 20% and primed for the second half.
Nasdaq likely to extend rally after Trump hails Israel-Iran ceasefire, sending oil prices tumbling
US stock futures are set to extend their gains on Tuesday, after Donald Trump oversaw a ceasefire deal agreement between Israel and Iran that sent oil prices tumbling. Futures contracts for the S&P 500 were up 0.7%, while those for the tech-heavy Nasdaq gained almost 1% and Dow Jones futures were up 0.6%.
3 Best Dividend Stocks in the Nasdaq Composite
Digging deep into the Nasdaq Composite will reveal hidden dividend-paying gems. Investors should focus on financially secure businesses as much as eye-catching dividend yields.
Caris Life Sciences IPO: All eyes on the stock price today as the AI cancer care firm makes its Nasdaq debut
On Wednesday morning, the cancer diagnostics biotech firm Caris Life Sciences rang Nasdaq's opening bell in New York, marking the company's awaited initial public offering.
Slide Insurance IPO: Stock price will be closely watched today as insurtech firm debuts on the Nasdaq
Slide Insurance Holdings is set to debut on the Nasdaq today. The residential insurance company out of Florida will make its initial public offering for $17 per share.
Sixth Street-backed Caris Life valued at $7.66 billion in strong Nasdaq debut
Caris Life Sciences' shares jumped nearly 29% in their New York debut on Wednesday, fetching the cancer diagnostic firm a valuation of $7.66 billion and signaling a growing investor appetite for new listings in 2025.
Nasdaq-traded Chinese herb company hits near $30 billion market value after speculative surge
Shares of Regencell Bioscience, a Hong Kong-based developer of traditional Chinese herbal treatments that it says can treat childhood ADHD and autism, more than tripled Monday. The stock soared more than 280% after a 38-for-1 stock split.
QQDN: Brand New, For Trading, Not Holding, Nasdaq
QQDN is a new leveraged ETF targeting -2x daily performance of the Nasdaq-100 Mega Index, designed for short-term speculation or hedging. Leveraged ETFs like QQDN are not suitable for long-term holding due to daily resets, derivative time decay, and volatility drag. Liquidity and trading volume are currently limited, so bid/ask spreads may be wide until the fund gains size and activity.
Chime IPO: Stock price today as financial services startup makes closely watched Nasdaq debut
Chime Financial is expected to debut on the Nasdaq today. The fintech company's initial public offering (IPO) is one of the most anticipated of 2025, and investors and market watchers will be eagerly waiting to see how the newly public stock performs on its first day of trading.
Chime prices IPO at $27 per share, valuing fintech company at $11.6 billion ahead of Nasdaq debut
Chime's decision to go public comes after a steep valuation cut and years of private market delays across the fintech sector. The company provides online banking services.
